About the Formulation This formulation combines two investigational peptide compounds: BPC-157 (Body Protection Compound-157) a synthetic peptide originally derived from a protective protein sequence identified in gastric juice and investigated in laboratory models of tissue biology and cellular signalling
Given the pre-existing data on GLP-1 and glucagon, we designed a double-blinded randomised cross-over study, in which we gave volunteers who were overweight short-term intravenous infusions of glucagon (50 ng/kg/min or 14 pmol/kg/min), GLP-1 (0.8 pmol/kg/min), combination of glucagon + GLP-1 at the same doses, or placebo over 45 minutes, and demonstrated that there was a significant increase in resting energy expenditure with glucagon alone which was preserved with the combination of glucagon + GLP-1, whereas GLP-1 did not affect energy expenditure (66)
Clinical studies have not established decreased libido as an official side effect, but the emerging case report literature and proposed neurochemical mechanisms suggest it occurs in a subset of women
Impact of STSegmentElevation Myocardial Infarction Regionalization Programs on the Treatment and Outcomes of Patients Diagnosed With NonSTSegmentElevation Myocardial Infarction
doi:10.1044/1059-0889(2011/10-0041)